ArticleAnnals of surgical oncology2025
Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing.Breast cancer (Tokyo, Japan) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRacial and ethnic breast cancer disparities persist. This may be reflected by differences in Oncotype DX recurrence scores (RS), which are higher for Black women. This study assesses the association between ancestry and RS.
methodsStage I-III hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with ancestry and RS data were prospectively identified from 2017 to 2021. RS were grouped into low, intermediate, and high categories. Multinomial regression determined the association between ancestry and RS controlling for ancestry and estrogen receptor (ER), progesterone receptor (PR), and HER2 expression.
resultsOf 174 patients, 28 (16.1%) self-identified as non-Hispanic White, 107 (61.5%) self-identified as Hispanic White, 19 (10.9%) self-identified as non-Hispanic Black, and 9 (5.2%) self-identified as Hispanic Black. Ninety-four (54.0%) patients had low RS, 51 (29.3%) had intermediate RS, and 29 (16.7%) had high RS. On multivariable analyses, West African ancestry was associated with increased odds of intermediate (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.00-1.04, p = 0.039) and high (OR 1.03, 95% CI 1.00-1.06, p = 0.022) RS. East Asian ancestry was associated with decreased odds of intermediate RS (OR 0.78, 95% CI 0.60-1.00, p = 0.048). Increasing ER (OR 0.43, 95% CI 0.23-0.82, p = 0.011), PR (OR 0.20, 95% CI 0.11-0.34, p < 0.001), and HER2 (OR 0.24, 95% CI 0.09-0.63, p = 0.004) expression were associated with lower odds of high RS.
conclusionIncreasing West African ancestry is associated with increased odds of high and intermediate RS, while increasing East Asian ancestry is associated with lower odds of intermediate RS. These findings require validation but suggest ancestry may represent a biological biomarker and that assays guiding adjuvant therapy may require ancestry-based calibration in HR+/HER2- tumors.
Indexed as
Identifiers
40014208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.